Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
La Oficina de Propiedad Intelectual de la Unión Europea cierra la solicitud de ayuda del Fondo para pymes (SME Fund) hasta la siguiente convocatoria en 2026.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
119
resultados
Última actualización
11/12/2025 [06:53:00]
Resultados 100 a 119 de 119
Resumen de: WO2025217563A1
A device for continuously monitoring glucose levels in a patient includes a lead assembly in electrical communication with an electronics assembly. The electronics assembly is configured to be positioned in the subcutaneous tissue and the lead assembly is configured to be positioned in a vessel of the patient, such as in a vein or in an epidural space. The lead assembly has a lumen, and includes at least one electrode in electrical communication with the electronics assembly.
Resumen de: WO2025216456A1
The present invention generally relates to implantable continuous blood glucose measurement technology. In particular, the present invention relates to an implantable continuous blood glucose measurement device for continuously measuring blood glucose in the body of a user, in which an oscillator for generating a variable frequency output signal corresponding to a voltage or current applied to both ends thereof is connected to a glucose fuel cell for generating electrical energy by glucose in the body, comprises an LED element, which is turned on or off by the output signal of the oscillator, or an antenna for wirelessly transmitting the output signal of the oscillator. The present invention has the advantage that blood glucose can be continuously measured in a state in which a blood glucose sensor is implanted in the body, without having to replace same.
Resumen de: WO2025216649A1
The invention relates to medicine and technology, and more particularly to non-invasively detecting a change in a person's blood glucose concentration, and can be used in the creation of devices for this purpose, as well as in the creation of socially-oriented systems for the early diagnosis of diabetes and associated diseases, in the form of a pen. The aim of the invention is to improve the operational efficiency of a device for non-invasively checking a person's blood glucose concentration by reducing the set-up and configuration time required. This aim is achieved in that a device for non-invasively checking a person's blood glucose concentration is based on a pen and has a sensor disposed on one end of a housing, opposite an end containing a device for applying ink to a surface. The technical results of the invention include: obviating the need for the device to be worn on an arm; simplifying the device by the absence of a strap and by incorporation of the device into a pen; and making it possible to visually check the correct positioning of the sensor of the device on a pulse point.
Resumen de: WO2025216236A1
This blood sugar level measurement apparatus comprises an estimation unit that estimates blood sugar levels in a living body by using a trained machine learning model. The machine learning model is a model for outputting output data relating to a blood sugar level by inputting, as an input parameter, at least a temporal phase difference between oxygenated hemoglobin and deoxygenated hemoglobin in blood of a living body.
Resumen de: WO2025216237A1
This blood glucose level measurement device comprises: a light output unit that outputs light; a light detection unit that detects the light output by the light output unit and transmitted through a living body; a temporal phase difference calculation unit that calculates, on the basis of the detection result from the light detection unit, a temporal phase difference between an oxygenated hemoglobin waveform pertaining to the oxygenated hemoglobin concentration in blood of the living body and a deoxygenated hemoglobin waveform pertaining to the deoxygenated hemoglobin concentration in the blood of the living body; a blood glucose level calculation unit that calculates the blood glucose level of the living body on the basis of the calculated temporal phase difference; and a confidence level estimation unit that estimates the confidence level of the calculated temporal phase difference. The confidence level estimation unit estimates that the confidence level of the temporal phase difference is lower when the SN ratio of the detection result from the light detection unit is lower.
Resumen de: US2025318763A1
Systems and methods of use for continuous analyte measurement of a host's vascular system are provided. In some embodiments, a continuous glucose measurement system includes a vascular access device, a sensor and sensor electronics, the system being configured for insertion into communication with a host's circulatory system.
Resumen de: US2025319257A1
The embodiments described herein may relate to methods and systems for adjusting insulin delivery. Some methods and systems may be configured to adjust insulin delivery to personalize automated insulin delivery for a person with diabetes. Some methods and systems may be configured to adjust insulin delivery to a person with diabetes according to one or more conditions of an insulin delivery device. Some methods and systems may be configured to enable a lock-out mode where adjustment to insulin delivery to personalize automated insulin delivery is restricted.
Resumen de: US2025319256A1
In an aspect, the present disclosure provides an insulin delivery device configured to be positioned on a body of a subject via a single puncture site in said body of said subject, wherein said insulin delivery device is configured to deliver an insulin or insulin analog formulation to said subject via said single puncture site, wherein said insulin delivery device comprises a sensor configured to measure a glucose concentration in said body of said subject via said single puncture site, and wherein said delivering and said measuring are performed at substantially the same time for a time period of at least 1 hour subsequent to said positioning, while maintaining a sensitivity of said sensor of at least 50% of an initial sensitivity of said sensor.
Resumen de: US2025319254A1
Techniques disclosed herein relate to managing operations of a dual-mode insulin delivery device that can operate in a manual insulin delivery mode and an automated closed-loop insulin delivery mode. In one example, a processor-implemented method includes obtaining insulin delivery data of an insulin delivery device collected while the insulin delivery device operates in a closed-loop mode, determining an updated value of a parameter of the insulin delivery device in a manual mode based on the insulin delivery data, and causing the insulin delivery device to deliver insulin in the manual mode based on the updated value of the parameter of the insulin delivery device, where the parameter of the insulin delivery device has separate values in the manual mode and the closed-loop mode.
Resumen de: US2025319255A1
A method may comprise (a) inserting an insulin delivery device subcutaneously into a body of a subject, which comprises an amperometric glucose sensor comprising an electrode layer comprising an indicating electrode and underlying a redox-catalytic layer comprising a redox mediator; (b) using said insulin delivery device to deliver an insulin formulation (e.g., comprising a phenol or cresol excipient) subcutaneously to said subject; and (c) using said amperometric glucose sensor to measure a subcutaneous glucose concentration, which comprises using said redox-catalytic layer to allow electron transfer from subcutaneous glucose to said indicating electrode sufficient to cause a response of said amperometric glucose sensor at an applied bias potential of no more than +250 millivolts, wherein (b) and (c) are performed at the same time for at least one hour, while maintaining a sensor sensitivity of at least 50% of an initial sensor sensitivity for up to one hour.
Resumen de: US2025318757A1
A device for continuously monitoring glucose levels in a patient includes a lead assembly in electrical communication with an electronics assembly. The electronics assembly is configured to be positioned in the subcutaneous tissue and the lead assembly is configured to be positioned in a vessel of the patient, such as in a vein or in an epidural space. The lead assembly has a lumen, and includes at least one electrode in electrical communication with the electronics assembly.
Resumen de: US2025318759A1
Systems and methods are described herein for utilizing a photoacoustic sensor for estimating analyte concentration levels. Also described here are calibration and training methods for calibrating and/or training an analyte sensor to more accurately estimate an analyte concentration level on the basis of a received acoustic signal.
Resumen de: US2025318756A1
A device for continuously monitoring glucose levels in a patient includes a lead assembly in electrical communication with an electronics assembly. The electronics assembly is configured to be positioned in the subcutaneous tissue and the lead assembly is configured to be positioned in a vessel of the patient, such as in a vein or in an epidural space. The lead assembly has a lumen, and includes at least one electrode in electrical communication with the electronics assembly.
Resumen de: US2025318729A1
Disclosed embodiments include methods and systems including a receiver unit of a glucose monitoring system. The receiver unit is configured to receive a key associated with a transmitter unit that enables the receiver unit to identify the transmitter unit, initiate communication with the transmitter unit, access a communication key uniquely associated with the transmitter unit, and receive communication packets from the remote transmitter unit on a periodic basis including data indicative of a glucose level of a bodily fluid. The receiver unit is further configured to process the data determine the glucose level for display, output a numerical representation of the determined glucose level in a GUI, and transmit data indicative of the glucose level to a second receiver unit.
Resumen de: US2025318755A1
Methods, systems, and devices for evaluating a user's metabolic balance are described. A system may include a wearable device and a glucose monitoring device. The system may acquire physiological data from the wearable device, and blood glucose data from the glucose monitoring device. The system may be configured to determine physiological characteristics of the user based on the physiological data, such characteristics associated with a sleep quality of the user, a stress level of the user, an activity level of the user, a recovery of the user, or any combination thereof. Similarly, the system may identify metabolic characteristics of the user, such as changes in the user's blood glucose data. By overlaying and comparing the physiological data and the blood glucose data, the system may be able to evaluate how the user's physiological characteristics affect or impact the user's metabolic characteristics, or vice versa.
Resumen de: US2025318758A1
A device for continuously monitoring glucose levels in a patient includes a lead assembly in electrical communication with an electronics assembly. The electronics assembly is configured to be positioned in the subcutaneous tissue and the lead assembly is configured to be positioned in a vessel of the patient, such as in a vein or in an epidural space. The lead assembly has a lumen, and includes at least one electrode in electrical communication with the electronics assembly.
Resumen de: AU2025200899A1
An embodiment may provide a method of providing an event notification in a glucose monitoring system, the method including determining whether an event occurs; in response to the occurrence of the event, determining whether an event occurrence time falls within a signal loss section; and outputting a notification corresponding to the event depending on whether the event occurrence time falls within the signal loss section. An embodiment may provide a method of providing an event notification in a glucose monitoring system, the method including determining whether an event occurs; in response to the occurrence of the event, determining whether an event occurrence time falls within a signal loss section; and outputting a notification corresponding to the event depending on whether the event occurrence time falls within the signal loss section. eb n e m b o d i m e n t m a y p r o v i d e a m e t h o d o f p r o v i d i n g a n e v e n t n o t i f i c a t i o n i n a e b g l u c o s e m o n i t o r i n g s y s t e m , t h e m e t h o d i n c l u d i n g d e t e r m i n i n g w h e t h e r a n e v e n t o c c u r s ; i n r e s p o n s e t o t h e o c c u r r e n c e o f t h e e v e n t , d e t e r m i n i n g w h e t h e r a n e v e n t o c c u r r e n c e t i m e f a l l s w i t h i n a s i g n a l l o s s s e c t i o n ; a n d o u t p u t t i n g a n o t i f i c a t i o n c o r r e s p o n d i n g t o t h e e v e n t d e p e n d i n g o n w h e t h e r t h e e v e n t o c c u r
Resumen de: EP4631428A1
Embodiments of the invention provide amperometric analyte sensors having optimized elements such as dexamethasone rejection membranes as well as methods for making and using such sensors. The amperometric analyte sensor apparatus comprises: a base layer; a conductive layer disposed on the base layer and comprising a working electrode; a dexamethasone rejection membrane disposed over an electroactive surface of the working electrode, wherein the interference rejection membrane comprises a poly Hema composition and an analyte sensing layer. While embodiments of the innovation can be used in a variety of contexts, typical embodiments of the invention include glucose sensors used in the management of diabetes.
Nº publicación: ES3038405T3 13/10/2025
Solicitante:
I SENS INC
i-Sens, Inc
Resumen de: AU2025203521A1
The present disclosure provides a continuous glucose monitoring device. The continuous glucose monitoring device comprises a body attachable unit configured to attach to a body; an applicator accommodating the body attachable unit, the applicator configured to guide the body attachable unit to be mounted on the body based on manipulation of a user; a housing comprising an inner case and an outer case; a plunger body movably disposed in the housing and configured to move from a first position to a second position along an insertion direction; a needle unit coupled to the plunger body; and a rotatable body being rotated based on a movement of the plunger body. The rotatable body is rotated when the plunger body moves from the first position to the second position. The rotatable body is positioned between the inner case and the plunger body to block movement of the plunger body in a withdrawal direction opposite to the insertion direction when the plunger body reaches the second position.
BOPI
Sede Electrónica
